Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of factors influence its efficacy.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
02
06
2020
accepted:
01
02
2021
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
29
6
2021
Statut:
epublish
Résumé
The antihelminthic drug praziquantel has been used as the drug of choice for treating schistosome infection for more than 40 years. Although some epidemiological studies have reported low praziquantel efficacy in cure rate (CR) and/or egg reduction rate (ERR), there is no consistent robust evidence of the development of schistosome resistance to praziquantel (PZQ). There is need to determine factors that lead to variable treatment CR and/or ERR. Therefore, we conducted a systematic review and meta-analysis to review CR and ERR as well as identify their predictors. In this systematic review and meta-analysis, a literature review was conducted using Biosis Citation Index, Data Citation Index, MEDLINE, and Web of Science Core Collection all of which were provided through Web of Science. Alongside these, EMBASE, and CAB abstracts were searched to identify relevant articles. Random effect meta-regression models were used to identify the factors that influence CR and/or ERR by considering differences in host characteristics and drug dose. In total, 12,127 potential articles were screened and 146 eligible articles (published from 1979 to 2020) were identified and included for the meta-analysis. We found that there has been no significant reduction in CR or ERR over the study period. The results showed more variability in CR, compared with ERR which was more consistent and remained high. The results showed a positive effect of "PZQ treatment dose" with the current recommended dose of 40 mg/kg body weight achieving 57% to 88% CR depending on schistosome species, age of participants, and number of parasitological samples used for diagnosis, and ERR of 95%. Based on a review of over 40 years of research there is no evidence to support concerns about schistosomes developing resistance to PZQ. These results indicate that PZQ remains effective in treating schistosomiasis.
Sections du résumé
BACKGROUND
The antihelminthic drug praziquantel has been used as the drug of choice for treating schistosome infection for more than 40 years. Although some epidemiological studies have reported low praziquantel efficacy in cure rate (CR) and/or egg reduction rate (ERR), there is no consistent robust evidence of the development of schistosome resistance to praziquantel (PZQ). There is need to determine factors that lead to variable treatment CR and/or ERR. Therefore, we conducted a systematic review and meta-analysis to review CR and ERR as well as identify their predictors.
METHODOLOGY/PRINCIPAL FINDINGS
In this systematic review and meta-analysis, a literature review was conducted using Biosis Citation Index, Data Citation Index, MEDLINE, and Web of Science Core Collection all of which were provided through Web of Science. Alongside these, EMBASE, and CAB abstracts were searched to identify relevant articles. Random effect meta-regression models were used to identify the factors that influence CR and/or ERR by considering differences in host characteristics and drug dose. In total, 12,127 potential articles were screened and 146 eligible articles (published from 1979 to 2020) were identified and included for the meta-analysis. We found that there has been no significant reduction in CR or ERR over the study period. The results showed more variability in CR, compared with ERR which was more consistent and remained high. The results showed a positive effect of "PZQ treatment dose" with the current recommended dose of 40 mg/kg body weight achieving 57% to 88% CR depending on schistosome species, age of participants, and number of parasitological samples used for diagnosis, and ERR of 95%.
CONCLUSIONS/SIGNIFICANCE
Based on a review of over 40 years of research there is no evidence to support concerns about schistosomes developing resistance to PZQ. These results indicate that PZQ remains effective in treating schistosomiasis.
Identifiants
pubmed: 33730095
doi: 10.1371/journal.pntd.0009189
pii: PNTD-D-20-00971
pmc: PMC7968639
doi:
Substances chimiques
Anthelmintics
0
Praziquantel
6490C9U457
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009189Subventions
Organisme : Department of Health
ID : 16/136/33
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT095831
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT082028MA
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Infect Dis Poverty. 2018 Jul 05;7(1):73
pubmed: 29986763
Int J Parasitol. 2016 Jun;46(7):417-24
pubmed: 27073078
Acta Trop. 2013 Nov;128(2):292-302
pubmed: 23022016
J Trop Med Hyg. 1988 Feb;91(1):13-7
pubmed: 3126306
Tropenmed Parasitol. 1984 Jun;35(2):95-9
pubmed: 6464192
PLoS Negl Trop Dis. 2012;6(10):e1864
pubmed: 23094120
Z Parasitenkd. 1977 Jul 21;52(2):129-50
pubmed: 410178
Parasitology. 1992;105 Suppl:S41-8
pubmed: 1308928
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29866859
Trop Med Int Health. 2010 May;15(5):614-8
pubmed: 20214757
Bull Soc Pathol Exot. 2001 Mar;94(1):42-5
pubmed: 11346982
PLoS Negl Trop Dis. 2015 Jun 18;9(6):e0003821
pubmed: 26086551
Acta Trop. 2013 Nov;128(2):275-83
pubmed: 23791803
Acta Trop. 2008 Jan;105(1):45-54
pubmed: 17996207
Trans R Soc Trop Med Hyg. 2019 Jan 1;113(1):1-3
pubmed: 31222345
Am J Trop Med Hyg. 2004 Dec;71(6):778-82
pubmed: 15642971
Mem Inst Oswaldo Cruz. 2015 Apr;110(2):209-14
pubmed: 25946244
Acta Trop. 1999 Jan 15;72(1):53-63
pubmed: 9924961
East Afr Med J. 1990 Aug;67(8):532-8
pubmed: 2124537
Tropenmed Parasitol. 1984 Jun;35(2):91-4
pubmed: 6464191
Parasitology. 1987 Apr;94 ( Pt 2):281-300
pubmed: 2438629
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3286
pubmed: 25412105
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2596
pubmed: 24367712
Trop Med Infect Dis. 2019 Jan 29;4(1):
pubmed: 30699922
PLoS Negl Trop Dis. 2020 Jun 22;14(6):e0008388
pubmed: 32569278
PLoS Negl Trop Dis. 2017 Feb 17;11(2):e0005372
pubmed: 28212414
PLoS Negl Trop Dis. 2015 May 14;9(5):e0003752
pubmed: 25973845
Trans R Soc Trop Med Hyg. 1987;81(6):947-51
pubmed: 3140436
PLoS Negl Trop Dis. 2014 Jul 17;8(7):e2975
pubmed: 25033291
Int J Parasitol. 2004 Mar 29;34(4):527-33
pubmed: 15013742
Parasit Vectors. 2011 Oct 17;4:201
pubmed: 22004571
Parasitology. 1991 Dec;103 Pt 3:363-70
pubmed: 1780173
Am J Trop Med Hyg. 2018 Aug;99(2):362-369
pubmed: 29893197
Trans R Soc Trop Med Hyg. 1988;82(1):115-6
pubmed: 3140441
PLoS Negl Trop Dis. 2020 Sep 25;14(9):e0008649
pubmed: 32976496
PLoS One. 2015 Apr 01;10(4):e0123673
pubmed: 25830917
Acta Trop. 1990 Oct;48(1):25-35
pubmed: 1980801
J Infect Dis. 1984 Aug;150(2):307-8
pubmed: 6470535
Lancet. 2014 Jun 28;383(9936):2253-64
pubmed: 24698483
Rev Cubana Med Trop. 1985 May-Aug;37(2):215-9
pubmed: 3938555
Trans R Soc Trop Med Hyg. 2008 Aug;102(8):759-66
pubmed: 18486169
PLoS Med. 2014 May 13;11(5):e1001640
pubmed: 24824051
Parasitology. 2009 Nov;136(13):1851-7
pubmed: 19281636
S Afr Med J. 1983 Jul 2;64(1):7-10
pubmed: 6344270
BMC Infect Dis. 2014 Apr 17;14:210
pubmed: 24742192
PLoS Negl Trop Dis. 2013;7(3):e2149
pubmed: 23556029
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000528
pubmed: 23450530
Expert Rev Anti Infect Ther. 2013 Jul;11(7):733-52
pubmed: 23879611
Am J Trop Med Hyg. 1974 Sep;23(5):902-9
pubmed: 4451230
PLoS Negl Trop Dis. 2014 Sep 11;8(9):e3139
pubmed: 25211217
Parasit Vectors. 2017 Jan 26;10(1):47
pubmed: 28126024
PLoS Negl Trop Dis. 2020 Oct 1;14(10):e0008650
pubmed: 33001969
PLoS Negl Trop Dis. 2011 Jun;5(6):e1165
pubmed: 21695161
PLoS Negl Trop Dis. 2011 May;5(5):e1143
pubmed: 21610855
Int J Parasitol. 2005 Jun;35(7):787-91
pubmed: 15925597
PLoS Comput Biol. 2011 Oct;7(10):e1002237
pubmed: 22028640
Am J Trop Med Hyg. 2006 Dec;75(6):1034-41
pubmed: 17172362
Trans R Soc Trop Med Hyg. 2012 Jul;106(7):400-7
pubmed: 22657533
Am J Trop Med Hyg. 2010 Oct;83(4):951-7
pubmed: 20889898
Lancet. 2001 Aug 25;358(9282):666-7
pubmed: 11545078
World Health Organ Tech Rep Ser. 2002;912:i-vi, 1-57, back cover
pubmed: 12592987
Parasite Immunol. 1997 Jun;19(6):255-63
pubmed: 9364555
Ann Trop Med Parasitol. 2003 Jan;97(1):37-51
pubmed: 12662421
Nat Med. 1999 Nov;5(11):1225-7
pubmed: 10545976
Int Health. 2010 Jun;2(2):103-13
pubmed: 20640034
Bull Soc Pathol Exot Filiales. 1985;78(5):643-7
pubmed: 3936631
Int J Parasitol. 2005 Nov;35(13):1453-7
pubmed: 16002073